Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jul 18:4:5743.
doi: 10.1038/srep05743.

An improved axillary staging system using the OSNA assay does not modify the therapeutic management of breast cancer patients

Miguel Alonso Ruano  1 , Eugeni Lopez-Bonet  2 , Maria Buxó  3 , Francesc Tuca-Rodríguez  1 , Ester Vila-Camps  1 , Elena Alvarez  1 , Begoña Martin-Castillo  4 , Javier A Menendez  5
Affiliations

An improved axillary staging system using the OSNA assay does not modify the therapeutic management of breast cancer patients

Miguel Alonso Ruano et al. Sci Rep. .

Abstract

The one-step nucleic acid amplification (OSNA) assay is a molecular procedure that can identify deposits of breast cancer (BC) cells in the sentinel lymph node (SLN). We examined the consistency of the OSNA assay with a classic hematoxylin-eosin (H&E)-based immunohistochemistry (IHC) study and evaluated how OSNA-based axillary staging might impact the therapeutic management of BC patients. SLN biopsy results were considered to be positive in 60 patients (40%) in the OSNA group (N = 148) and in 43 (28%) patients in the IHC cohort (N = 153, p = 0.023). There was no difference in the macrometastasis (22% for OSNA, 15% for H&E, p = 0.139) or micrometastasis (19% for OSNA, 13% for H&E, p = 0.166) rates, but we found statistically significant differences in the number of isolated tumor cells (1% for OSNA, 11% for H&E, p < 0.001). There were no differences in the administration rate of adjuvant systemic therapy between the OSNA (66% in the SLN(+) patients) and the H&E (74% in the SLN(+) patients) groups (p = 0.159). The OSNA assay allows for the detection of SLN metastases more precisely than conventional pathologic methods but does not alter the therapeutic management of SLN(+) BC patients.

PubMed Disclaimer

References

    1. Giuliano A. E. et al. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann. Surg. 222, 394–401 (1995). - PMC - PubMed
    1. Wilson L. L. & Giuliano A. E. Sentinel lymph node mapping for primary breast cancer. Curr. Oncol. Rep. 7, 12–17 (2005). - PubMed
    1. Fleissig A. et al. Post-operative arm morbidity and quality of life. Results of the ALMANAC randomised trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer. Breast Cancer Res. Treat. 95, 279–293 (2006). - PubMed
    1. Cserni G. Intraoperative analysis of sentinel lymph nodes in breast cancer by one-step nucleic acid amplification. J. Clin. Pathol. 65, 193–199 (2012). - PubMed
    1. Tew K., Irwig L., Matthews A., Crowe P. & Macaskill P. Meta-analysis of sentinel node imprint cytology in breast cancer. Br. J. Surg. 92, 1068–1080 (2005). - PubMed

Publication types